Listed

American Vanguard Corp: Form 10-Q for the period ended Jun 30, 2020

Filed with the SEC on Aug 7, 2020 and accepted by EDGAR at Aug 7, 2020, 14:59 ET.

Share

Management's discussion and analysis

As filed, 39,436 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

MANAGEMENT OVERVIEW

The Company’s Operations in the Context of the COVID-19 Pandemic

In March 2020, the World Health Organization categorized the novel coronavirus (COVID-19) as a pandemic, and it continues to spread across the world. To limit the spread of the contagion, governments have taken various actions to slow and otherwise control the spread of the pandemic, including the issuance of stay-at-home orders, social distancing guidelines and border restrictions. At its outset, the Company took swift action to understand, contain and mitigate the risks posed by this pandemic. Specifically, we formed the Pandemic Work Group with a mission to ensure the health and safety of the workforce while ensuring continuity of the business. In the workplace, we have designed and implemented protocols for social distancing, made provisions for the workforce to work remotely where possible, and established quarantine policies for those who present COVID-like symptom or may have been in touch with those who have. Further, the group keeps current with local, state, federal and international laws and restrictions that could affect the business; provides real-time information to the workforce; and draws from political commentary and news statements concrete directions on how best to continue operations. We have also prepared contingency plans to permit the continued operation of our factories, in the event that there are critical staffing issues due to attrition. In addition, in April 2020, we amended our credit facility to support future working capital needs (see note 10 to the Condensed Consolidated Financial Statements). Further, we continuously monitor supply chain, transport, logistics and border closures and have reached out to third parties to make clear that we are continuing to operate, that we have our own policies relating to health (e.g., no third party visitors, no face-to-face meetings) and are committed to compliance with COVID-19 policies of our business partners. Our CEO and the Pandemic Work Group are holding weekly “state of the company” calls with the functional heads of our businesses across the globe to ensure that our information is shared in a timely manner and that our direction is clear.

It is important to understand that under applicable federal guidelines (at https://www.cisa.gov), the Company is part of the nation’s “critical infrastructure” and falls within three of the 16 sectors that are specially permitted to operate: “Food and Agriculture” sector (engaged in “the production of chemicals and other substances used by the food and agriculture industry, including pesticides, herbicides etc.”), the “Chemical” sector (supporting the operation . . . of facilities (particularly those with high risk chemicals . . . whose work cannot be done remotely and requires the presence of highly trained personnel to ensure safe operations”) and the “Public Works and Infrastructure Support Services” sector (in support of public health including pest control and exterminators, landscapers and others who provide services to residences and businesses). In issuing guidance on Coronavirus, President Trump said, “If you work in a critical infrastructure industry, as defined by the Department of Homeland Security, such as healthcare services and pharmaceutical and food supply, you have a special responsibility to maintain your normal work schedule [emphasis added].” We have found that state COVID-19 orders and, indeed, even those of countries in which the outbreak has been most pronounced have consistently excepted food supply as an area essential to the survival of its populations and, as such, had given special permission to companies, such as ours, to continue to operate during the pandemic.

In keeping with our charge to operate as an essential business and by virtue of our efforts to contain and mitigate the risks posed by the pandemic, we have been able to manage our business with minimal disruption during the reporting period. As mentioned earlier (see Note 1 to the Condensed Consolidated Financial Statements), the coronavirus has affected our overall performance to a degree. Lost opportunities for certain new product launches, inability to meet potential new customers face-to-face, reduced demand for commodity crops sold to restaurants, and foreign exchange effects in Brazil, Mexico and Australia, have likely limited the Company’s top-line growth by up to several million dollars and the associated profitability, to an indeterminate degree, since the inception of the pandemic.

Overview of the Company’s Performance

Despite the fact that the pandemic continued in force and increasingly shifted to our primary markets (US, LATAM and Brazil) during the second quarter, the Company’s overall operating results were, on balance, strong. While net sales declined by 8% (to $104,555 in 2020 from $113,104 in 2019), cost of sales dropped even more (by approximately 10% to $64,249 from $71,451), and gross profit declined only 3% ($40,306 v. $41,653). Consequently, gross margin increased to 39% from 37% of net sales due largely to improved factory utilization during the period. Operating expenses decreased quarter-over-quarter by about 5% (to $33,555 in 2020 from $35,362 in 2019). In 2019, operating expenses included benefits from the re-valuation of deferred purchase price consideration ($1,345), and a break-up fee associated with a potential acquisition ($500), which did not recur in 2020. In light of improved factory performance, tighter control of operating expenses (including, for example, reduced product development, research and regulatory expenses and curtailment of travel and entertainment during the pandemic), lower interest rate expenses and a slightly higher effective tax rate, net income for the quarter rose by 25% (to $3,887 in 2020 from $3,106 in 2019). In short, the Company was able to generate higher profitability on an absolute basis, despite a reduced top line in the midst of a global pandemic.

Details on our financial performance are set forth below.

RESULTS OF OPERATIONS

Quarter Ended June 30, 2020 and 2019:

Net sales: 2020 2019 Change % Change
US crop $44,670 $47,575 $(2,905) -6%
US non-crop 13,872 16,955 (3,083) -18%
Total US 58,542 64,530 (5,988) -9%
International 46,013 48,574 (2,561) -5%
Total net sales: $104,555 $113,104 $(8,549) -8%
Cost of sales:
US crop $22,912 $28,592 $(5,680) -20%
US non-crop 6,843 8,661 (1,818) -21%
Total US 29,755 37,253 (7,498) -20%
International 34,494 34,198 296 1%
Total cost of sales: $64,249 $71,451 $(7,202) -10%
Gross profit:
US crop $21,758 $18,719 $3,039 16%
US non-crop 7,029 8,558 (1,529) -18%
Total US 28,787 27,277 1,510 6%
International 11,519 14,376 (2,857) -20%
Total gross profit $40,306 $41,653 $(1,347) -3%
Gross margin:
US crop 49% 39%
US non-crop 51% 50%
Total US 49% 42%
International 25% 30%
Total gross margin 39% 37%

Our domestic crop business recorded net sales that were about 6% lower than those of second quarter 2019 ($44,670 v. $47,575). When viewed by type of product and crop, sales were mixed. In general, during the second quarter, the distribution channel adopted conservative procurement practices in light of the COVID-19 pandemic, price trends for crop commodities prices and concerns relating to near-term export demand. Sales of our lower-margin burn-down herbicide Parazone® and our fungicide Equus® decreased during the quarter. In addition, a significant decline in planted cotton acres from lower commodity prices resulted in a drop in net sales of our foliar insecticide Bidrin. Further, our Impact® post-emergent herbicide generated reduced sales. Partially offsetting these reductions, are our recently acquired herbicide products Classic®, First Rate® and Python®, used primarily on soybeans, all contributed positively during the period. Further, net sales of our corn soil insecticides, led by our premium brand Aztec®, were higher during the quarter.

Cost of sales within the domestic crop business was considerably lower than the second quarter of 2019, generating a 16% increase in gross profit (from $18,719 to $21,758). This improvement rose from increased sales of recently introduced, higher margin products and improved factory performance. As a result, gross profit margin rose to 49% for our crop business during the second quarter as compared to 39% for the comparable period last year.

Our domestic non-crop business showed decreased net sales (down about 18% to $13,872 from $16,955) quarter-over-quarter. In this category, our Dibrom® mosquito adulticide sales accounted for more than the entire decline, influenced by timing shifts in customer procurement relative to the prior year. Partially offsetting this decline, we received increased royalty fees for our Envance essential oil technology as compared to the second quarter of 2019. We expect to recognize additional royalty fees during the remaining quarters of 2020 and in future years. Net sales from our OHP nursery and ornamental business were flat with last year, as demand for homeowner garden and landscape products in big box stores remained steady in spite of pandemic restrictions at retail locations around the country.

Cost of sales within the domestic non-crop business declined by about 21% (from $8,661 to $6,843) quarter-over-quarter. This decrease was influenced by quarterly product mix with a portion of sales coming from the Envance natural oils licensing fees which carry no cost of goods component. Gross profit for domestic non-crop decreased by 18% (from $8,558 in 2019 to $7,029 in 2020); by contrast, gross profit margin for the non-crop business increased to 51% for the quarter as compared to 50% during the second quarter of 2019.

Net sales of our international businesses were down by about 5% during the period ($46,013 in 2020 v. $48,574 in 2019). Several factors contributed to this result. In Europe, sales of our Mocap® insecticide dropped sharply in connection with the phase-out of that product following the cancellation of its registration in the EU. Sales performance was down about 5% in Central America largely due to difficulties experienced with in-field sales restrictions from the COVID-19 pandemic. Mexico sales reflected steady demand for granular insecticides, bromacil herbicides and soil fumigants, offset by some sales that were missed due to production difficulties at our regional toll manufacturer. In Brazil, net sales declined due to portfolio streamlining (to optimize our sales resources) and delays in procurement arising from economic uncertainty. The performances of our Brazilian and Mexican businesses were further affected by a devaluation in the Brazilian real and the Mexican peso.

Cost of sales in our international business increased slightly (about 1%) from $34,198 in 2019 to $34,494 in 2020. Gross profit for International declined by approximately 20% from $14,376 in 2019 to $11,519 in 2020, and gross profit margin dropped from 30% in 2019 to 25% in the second quarter of 2020.

On a consolidated basis, gross profit for the quarter decreased by 3% (from $41,653 in 2019 to $40,306 in 2020). However, the change in mix described above had the impact of increasing gross margin percentage by approximately 2% and included a much improved quarter-over-quarter factory performance. Overall gross margin percentage improved to 39% in the quarter, as compared to 37% in the quarter of the prior year.

Operating expenses decreased by $1,807 to $33,555 for the three months ended June 30, 2020, as compared to the same period in 2019. The differences in operating expenses by department are as follows:

2020 2019 Change % Change
Selling $10,031 $11,770 $(1,739) -15%
General and administrative 10,491 9,182 1,309 14%
Research, product development and regulatory 6,104 6,856 (752) -11%
Freight, delivery and warehousing 6,929 7,554 (625) -8%
$33,555 $35,362 $(1,807) -5%
  • Selling expenses decreased by $1,739 to end at $10,031 in the three months ended June 30, 2020 as compared to the same period of the prior year. The main drivers were the reduction in advertising and promotion costs, the favorable impact of lower foreign currency exchange rates (as they relate to operating expenses of certain foreign subsidiaries) and decreased travel and entertainment expenses across all of our global operating subsidiaries, as a result of restrictions imposed in response to the COVID-19 pandemic.
  • General and administrative expenses increased by $1,309 to end at $10,491 for the three months ended June 30, 2020, as compared to the same period of 2019. In 2019, operating expenses included beneficial adjustments to the fair value of acquisition related deferred consideration liabilities ($1,345) and a break-up fee associated with a potential acquisition ($500). There were no similar benefits recorded in the second quarter of 2020. These comparative increases were partially offset by lower legal expenses and by reduced travel and entertainment expenses as a result of the COVID-19 pandemic
  • Research, product development costs and regulatory expenses decreased by $752 to end at $6,104 for the three months ended June 30, 2020, as compared to the same period of 2019. The main drivers were decreases in our product defense and product development costs, primarily resulting from general delays in activities with third party service providers caused by pandemic related disruption.
  • Freight, delivery and warehousing costs for the three months ended June 30, 2020 were $6,929 or 6.6% of sales as compared to $7,554 or 6.7% of sales for the same period in 2019. This change in cost was primarily driven by the reduced overall sales volume recorded in 2020, as compared to the same period of the prior year.

Interest costs net of capitalized interest were $1,274 during the three months ended June 30, 2020, as compared to $1,925 in the same period of 2019. Interest costs are summarized in the following table:

Average Indebtedness and Interest expense

Three months ended June 30, 2020 Average Debt Interest Expense Interest Rate Three months ended June 30, 2019 Average Debt Interest Expense Interest Rate
Revolving line of credit (average) $185,989 $1,248 2.7% $178,616 $1,908 4.3%
Amortization of deferred loan fees — 80 — — 53 —
Amortization of other deferred liabilities — 3 — — — —
Other interest (income) expense — 26 — — 47 —
Subtotal 185,989 1,357 2.9% 178,616 2,008 4.5%
Capitalized interest — (83) — — (83) —
Total $185,989 $1,274 2.7% $178,616 $1,925 4.3%

The Company’s average overall debt for the three months ended June 30, 2020 was $185,989, as compared to $178,616 for the three months ended June 30, 2019. During the quarter, we continued to focus on managing our working capital for our expanded business and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 2.7% for the three months ended June 30, 2020, as compared to 4.3% in 2019. The lower interest cost recorded in the three months ended June 30, 2020, as compared to the same period of the prior year, was substantially due to lower interest rates on borrowings in the US, which was part of Federal Government efforts to stimulate the overall economy.

Income tax expense was $1,565 for the three months ended June 30, 2020, as compared to $1,224 for the comparable period in 2019. The effective tax rate for the quarter was 28.6%, as compared to 28.0% in the same period of the prior year. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management. The increase in effective tax rate is primarily driven by the mix of our domestic and international income.

During the three months ended June 30, 2020 and 2019, we recognized losses of $25 and $36, respectively, on our investment in the Hong Kong joint venture, which is a 50% owned equity investment.

Our overall net income for the three months ended June 30, 2020 was $3,887 or $0.13 per basic and diluted share, as compared to $3,106 or $0.11 per basic and diluted share in the same period of 2019.

Six Months Ended June 30, 2020 and 2019:

Overview of the Company’s Performance

The first six months of 2020 were shaped, in part, by the advent of the coronavirus, which expanded with increasing effect into regions primarily served by the Company. Domestic markets within our industry were slowed during the first quarter but gained traction in the second. By contrast, our international businesses enjoyed greater consistency during the first quarter and saw softer markets in the second. All told, the Company’s overall operating results for the first six months of 2020 declined as compared with those of the same period of 2019. Net sales were down about 6% ($200,517 compared to $212,780) and gross profit was down 6% ($78,687 v. $83,355). Gross margin remained the same at 39% of net sales, and operating expenses were essentially flat ($70,100 v. $70,162). Net income ended at $4,407, as compared to $7,012 for the same period of 2019.

On a consolidated basis, with domestic sales down 5% and international sales down by about 7%, overall net sales were down by about 6% (or $12,263). Cost of sales were down 6% on an absolute basis, while, as a percent of net sales, they remained at 61%. Factory performance was improved during the first half of 2020 as compared to that of 2019. These factors, taken together, yielded a decline in gross profit of $4,668. In the first half of 2020 operating expenses remained flat on an absolute basis, with considerably lower sales and marketing expenditures due largely to reduced travel and entertainment activities and customer visit limitations caused by restrictions in place related to the pandemic. Operating expenses as a percent of net sales rose from 33% to 35% for the period. It should be noted that, during the first half of 2019, the Company benefitted from a credit of about $2,888 relating to deferred purchase price consideration, and no such credit was recorded in 2020. Consequently, operating income for the period decreased by $4,606. After significantly lower interest expense and a higher overall effective tax rate, net income for the period declined to $4,407 from $7,012 during the first half of the prior year. Details on our financial performance are set forth below.

RESULTS OF OPERATIONS

Six months ended June 30, 2020 and 2019

Net sales: 2020 2019 Change % Change
US crop $95,032 $97,845 $(2,813) -3%
US non-crop 24,865 28,222 (3,357) -12%
Total US 119,897 126,067 (6,170) -5%
International 80,620 86,713 (6,093) -7%
Total net sales: $200,517 $212,780 $(12,263) -6%
Cost of sales:
US crop $49,029 $55,027 $(5,998) -11%
US non-crop 13,117 13,929 (812) -6%
Total US 62,146 68,956 (6,810) -10%
International 59,684 60,289 (605) -1%
Total cost of sales: $121,830 $129,245 $(7,415) -6%
Gross profit:
US crop $46,003 $42,214 $3,789 9%
US non-crop 11,748 14,872 (3,124) -21%
Total US 57,751 57,086 665 1%
International 20,936 26,269 (5,333) -20%
Total gross profit $78,687 $83,355 $(4,668) -6%
Gross margin:
US crop 48% 43%
US non-crop 47% 53%
Total US 48% 45%
International 26% 30%
Total gross margin 39% 39%

Our domestic crop business recorded net sales that were about 3% below than those of first half of 2019 ($95,032 v. $97,845). When viewed by type of product and crop, sales were mixed. During the first half, we saw careful procurement patterns in the domestic market, as low crop commodity prices and concerns about near-term demand from Asia caused growers and retailers to purchase crop protection inputs at a cautious and deliberate pace. Also, with a significant decline in planted cotton acres (relating to lower commodity prices), we experienced a first half drop in net sales of Bidrin® products. We also saw a (first quarter) decrease in sales of our NAA plant growth regulator used primarily on tree nuts and pome fruits, which arose in large part from timing of orders by certain of our larger customers. Partially offsetting these declines, soil fumigants posted a 17% increase during the first six months of 2020 due to strong performance in the first quarter, as drier weather conditions in California and the Pacific Northwest facilitated more widespread product application than had been the case early in 2019. With respect to our corn products, net sales of corn soil insecticides, including Aztec®, SmartChoice® and Counter®, were up in the first half, while our Impact® herbicide experienced decreased sales in part as a result of some product formulation issues that were substantially resolved during the quarter. Recently acquired products, including our rice herbicide Arroz®, our soybean herbicides (FirstRate, Classic and Python) and our miticide Stifle, added a strong incremental upside during the first half of the year.

Cost of sales within the domestic crop business declined 11%, as compared to the first six months of 2019, driven by mix of products, including the recently acquired products detailed above, and the improved factory performance in the first half of 2020, as compared to the same period of 2019. As a result, gross profit rose by about 9% (from $42,214 to $46,003).

Our domestic non-crop business recorded a decrease in net sales (down about 12% to $24,865 from $28,222) versus the first half of 2019. In this category, our Dibrom® mosquito adulticide sales declined significantly, influenced by relatively full channel inventories and timing shifts in customer procurement and relatively low pest pressure for the first half of the year. We expect demand for Dibrom will strengthen during the balance of 2020 with tropical storm activity predicted to intensify. Royalty fees for our Envance essential oil technology were comparable to the first half of last year; and we expect to recognize additional license fees and royalties during the balance of 2020. Driven by first quarter performance, our OHP nursery and ornamental business posted increased sales, as demand for homeowner garden and landscape products in big box stores remained strong in spite of pandemic restrictions at retail locations.

Cost of sales within the domestic non-crop business declined by about 6% (from $13,929 to $13,117) during the first half of 2020 versus the comparable period in 2019. Gross profit for domestic non-crop decreased by 21% (from $14,872 in 2019 to $11,748 in 2020) due primarily to lower sales of our highly profitable Dibrom mosquito adulticide.

Net sales of our international businesses were down by about 7% during the period ($80,620 in 2020 v. $86,713 in 2019). Several factors contributed to this result. In Europe, sales of our Mocap® insecticide declined during the phase-out of that product following the cancellation of its registration in the EU. In Canada, we experienced a sharp decline in Assure II sales as a result of intense second quarter price competition; the Company elected to maintain brand value rather than match the downward price trend. Sales performance was down slightly in Central America resulting from COVID-19 limitations on in-person/field sales & marketing efforts. Mexico posted improved sales with continuing demand for granular insecticides, bromacil herbicides, and soil fumigants for use on high-value vegetable crops. In Brazil, net sales declined due to lower first half disease pressure in soybeans (reducing demand for our fungicide products), portfolio streamlining and delays in procurement arising from uncertainty relating to the economy and the spread of the pandemic. The performances of our Brazilian and Mexican businesses, as reported in our Condensed Consolidated Financial Statements, were further affected by a devaluation in the Brazilian real and the Mexican peso. The average exchange rate of the Brazilian real and the Mexican peso decreased by approximately 21% and 11% for the six month period ended June 30, 2020 compared to the same period in the prior year.

Cost of sales in our international business decreased by 1% (from $60,289 in 2019 to $59,684 in 2020) primarily driven by mix and currency changes. Gross profit for the international businesses dropped by about 20% (from $26,269 in 2019 to $20,936 in 2020). This resulted from reduced sales of certain high margin products, including Mocap insecticide, Bromacil and Assure II herbicides. In addition, we experienced higher sales of low-margin products from our business in Australia.

On a consolidated basis, gross profit for the six months of 2020 decreased by 6% (from $83,355 in 2019 to $78,687 in 2020), as a result of reduced sales volumes detailed above. Factory performance was significantly better in the first six months of 2020, as compared to the same period of 2019. Gross margin performance, when expressed as a percentage of sales, remained flat at 39%.

Operating expenses decreased by $62 to $70,100 for the six months ended June 30, 2020, as compared to the same period in 2019. The differences in operating expenses by department are as follows:

2020 2019 Change % Change
Selling $20,505 $22,697 $(2,192) -10%
General and administrative 22,996 20,473 2,523 12%
Research, product development and regulatory 12,257 12,539 (282) -2%
Freight, delivery and warehousing 14,342 14,453 (111) -1%
$70,100 $70,162 $(62) 0%
  • Selling expenses decreased by $2,192 to end at $20,505 for the six months ended June 30, 2020, as compared to the same period of 2019. The main drivers were the reduction in advertising and promotion costs, the favorable impact of lower foreign currency exchange rates (as they relate to the translation of operating expenses of certain foreign subsidiaries) and decreased travel and entertainment activities across our global operating subsidiaries, as a result of restrictions imposed in response to the COVID-19 pandemic.
  • General and administrative expenses increased by $2,523 to end at $22,996 for the six months ended June 30, 2020, as compared to the same period of 2019. In 2019, operating expenses included beneficial adjustments related to the fair value of acquisition related deferred consideration liabilities ($2,888) and a break-up fee associated with a potential acquisition ($500). There were no similar benefits recorded in the second quarter of 2020. The increase also includes foreign exchange transaction losses experienced by our foreign subsidiaries. These increases were partially offset by decreases associated with reduced incentive compensation reflecting our financial performance during the first six months of 2020, reduced legal expenses, and from reduced travel and entertainment expenses in response to the COVID-19 pandemic.
  • Research, product development costs and regulatory expenses decreased by $282 to end at $12,257 for the six months ended June 30, 2020, as compared to the same period of 2019. The main drivers were decreases in our product defense and product development costs.
  • Freight, delivery and warehousing costs for the six months ended June 30, 2020 were $14,342 or 7.2% of sales as compared to $14,453 or 6.8% of sales for the same period in 2019. This change reflects lower overall sales offset by a change in the mix of product shipped and associated delivery destinations during the period.

Interest costs net of capitalized interest were $2,782 in the first six months of 2020, as compared to $3,537 in the same period of 2019. Interest costs are summarized in the following table:

Average Indebtedness and Interest expense

Six months ended June 30, 2020 Average Debt Interest Expense Interest Rate Six months ended June 30, 2019 Average Debt Interest Expense Interest Rate
Revolving line of credit (average) $175,475 $2,744 3.1% $160,782 $3,485 4.3%
Amortization of deferred loan fees — 139 — — 103 —
Amortization of other deferred liabilities — 6 — — — —
Other interest (income) expense — 57 — — 59 —
Subtotal 175,475 2,946 3.4% 160,782 3,647 4.5%
Capitalized interest — (164) — — (110) —
Total $175,475 $2,782 3.2% $160,782 $3,537 4.4%

The Company’s average overall debt for the six months ended June 30, 2020 was $175,475, as compared to $160,782 for the six months ended June 30, 2019. During the period, we continued to focus on our usage of revolving debt, while funding working capital for the newly acquired products and businesses. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 3.1% for the six months ended June 30, 2020, as compared to 4.3% in 2019.

Income tax expense decreased by $1,224 to end at $1,360 for the six months ended June 30, 2020, as compared to income tax expense of $2,584 for the comparable period in 2019. The effective tax rate for the six months ended June 30, 2020 was 23.4%, which included two discrete income tax benefits during the six months ended June 30, 2020. First, the Company assessed its income tax positions to account for the Coronavirus Aid Relief and Economic Security Act (“CARES Act”) which was signed into law on March 27, 2020. A provision of the act modified the amount of interest deduction allowed and therefore reduced the Company’s 2019 Global Intangible Low Tax Income (“GILTI”) inclusion. Second, the Company benefited from the tax impact of the vesting of certain stock grants. During the six months ended June 30, 2019, the Company’s effective tax rate was 26.8%. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the six months ended June 30, 2020 and 2019, the Company recognized losses of $38 and $60, respectively, on its investment in the Hong Kong joint venture which is a 50% owned equity investment.

Our overall net income for the six months ended June 30, 2020 was $4,407 or $0.15 per basic and diluted share, as compared to $7,012 or $0.24 per basic and diluted share in the same period of 2019.

LIQUIDITY AND CAPITAL RESOURCES

The Company’s operating activities provided net cash of $5,688 during the six months ended June 30, 2020, as compared to utilizing $32,086 during the six months ended June 30, 2019. Included in the $5,688 are net income of $4,407, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $11,776, and provision for bad debts in the amount of $392. Also included are stock-based compensation of $2,545, losses from equity method investment of $38, decrease in deferred income taxes of $1,562 and net foreign currency adjustment of $594. These together provided net cash inflows of $18,190, as compared to $18,517 for the same period of 2019.

During the six months of 2020, the Company increased working capital by $7,381, as compared to an increase of $48,935 during the same period of the prior year. Included in this change: inventories increased by $21,706 (normal at this point in the season), as compared to $27,635 for the first half of 2019. Deferred revenue decreased by $2,431, as compared to $19,438 in the same period of 2019, driven by customer decisions regarding demand, payment timing and our cash incentive programs. Our accounts payable balances decreased by $12,351, as compared to $10,224 in the same period of 2019, reflecting slower production activity this year in efforts to control inventory level. Accounts receivables decreased by $16,421, as compared to $7,841 in the same period of 2019. Prepaid expenses increased by $2,297, as compared to $1,844 in the same period of 2019. Income tax receivable net decreased by $899, as compared to an increase by $4,480 in the prior year. Accrued programs increased by $12,577, as compared to $11,823 in the prior year. The change reflected some changes in product mix and domestic programs. Finally, other payables and accrued expenses decreased by $3,621, as compared to $6,719 in the prior year as a result of the reduced incentive compensation accrual.

With regard to our program accrual, the increase (as noted above) primarily reflects our mix of sales and customers in the first six months of 2020, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the six months of 2020, the Company made accruals for programs in the amount of $33,336 and made payments in the amount of $20,771. During the first six months of the prior year, the Company made accruals in the amount of $29,220 and made payments in the amount of $17,397.

Cash used for investing activities was $11,465 for the six months ended June 30, 2020, as compared to $31,518 for the six months ended June 30, 2019. The Company spent $6,386 on fixed assets acquisitions primarily focused on continuing to invest in manufacturing infrastructure and $5,079 on investments and intangible assets.

During the six months ended June 30, 2020, financing activities provided $7,211, as compared to $63,523 for the same period of the prior year. This is principally from the reduced borrowings on the Company’s senior credit facility. In the first half of 2020, the Company paid dividends to stockholders amounting to $1,168, as compared to $1,160 in the same period of 2019.

The Company has a revolving line of credit that is shown as long-term debt in the Condensed Consolidated Balance Sheets at June 30, 2020 and December 31, 2019. These are summarized in the following table:

Long-term indebtedness ($000's) June 30, 2020 December 31, 2019
Revolving line of credit $160,000 $149,300
Deferred loan fees (593) (534)
Net long-term debt $159,407 $148,766

At June 30, 2020, the Company is compliant with all covenants to its Senior Credit Facility. Based on its performance against the most restrictive covenants in the Credit Agreement (see, supra Note 10), the Company had the capacity to increase its borrowings by up to $49,420, according to the terms thereof. This compares to an available borrowing capacity of $30,557 as of June 30, 2019 and $26,977 at December 31, 2019. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for both the trailing twelve month period and on a proforma basis arising from acquisitions, (2) net borrowings, (3) the leverage covenant (the Consolidated Funded Debt Ratio).

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our amended senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 15 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued accounting standards.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2019, except for the adoption of Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326)”, along with related clarifications and improvements.

Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the Condensed Consolidated Financial Statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.

Market risk

As filed, 1,172 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019.

The Company faces market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency as to foreign subsidiaries’ revenues, expenses, assets and liabilities. The Company currently does not engage in hedging activities with respect to such exchange rate risks.

Assets and liabilities outside the U.S. are located in regions where the Company has subsidiaries or joint ventures: Central America, South America, North America, Europe Asia, and Australia. The Company’s investments in foreign subsidiaries and joint ventures with a functional currency other than the U.S. dollar are generally considered long-term. Accordingly, the Company does not hedge these net investments.

Controls and procedures

As filed, 1,056 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As of June 30, 2020, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of June 30, 2020, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

Risk factors

As filed, 2,094 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2019, filed on March 10, 2020. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors, except for the following:

The Covid-19 pandemic is creating risk, uncertainty and adverse conditions in many industries both here and abroad. The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how the pandemic has impacted and may, in the future, impact its customers, business partners, and employees. While the Company did not incur significant disruptions from the COVID-19 pandemic during the three and six months ended June 30, 2020, the coronavirus did have the effect of limiting sales on new product launches, limiting interactions with potential new customers, reducing demand for products used on crops that are purchased by restaurants, and negatively impacted foreign currency exchange rates in Brazil, Mexico and Australia. The Company is unable to predict the impact that the pandemic will have on its financial condition, results of operations and cash flows in future reporting due to numerous uncertainties. The extent to which the COVID-19 pandemic impacts the Company’s operations and those of its customers will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. There is no guarantee that the Company will be able to operate without material disruption for the duration of the pandemic or that its financial conditions and results of operations will not be materially adversely affected by the pandemic in future quarters.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-04-01 to 2020-06-30$104.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2020-01-01 to 2020-06-30$200.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-04-01 to 2020-06-30$64.2mus-gaap:CostOfRevenue
Cost of revenue6 months2020-01-01 to 2020-06-30$121.8mus-gaap:CostOfRevenue
Gross profit3 months2020-04-01 to 2020-06-30$40.3mus-gaap:GrossProfit
Gross profit6 months2020-01-01 to 2020-06-30$78.7mus-gaap:GrossProfit
Operating income3 months2020-04-01 to 2020-06-30$6.8mus-gaap:OperatingIncomeLoss
Operating income6 months2020-01-01 to 2020-06-30$8.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-04-01 to 2020-06-30$1.3mus-gaap:InterestExpense
Interest expense6 months2020-01-01 to 2020-06-30$2.8mus-gaap:InterestExpense
Income tax3 months2020-04-01 to 2020-06-30$1.6mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2020-01-01 to 2020-06-30$1.4mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-04-01 to 2020-06-30$3.9mus-gaap:NetIncomeLoss
Net income6 months2020-01-01 to 2020-06-30$4.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-04-01 to 2020-06-30$0.13us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2020-01-01 to 2020-06-30$0.15us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-04-01 to 2020-06-30$0.13us-gaap:EarningsPerShareBasic
Basic EPS6 months2020-01-01 to 2020-06-30$0.15us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-04-01 to 2020-06-3029,854,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2020-01-01 to 2020-06-3029,904,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2020-01-01 to 2020-06-30$5.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Dividends paid6 months2020-01-01 to 2020-06-30$1.2mus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2020-06-30$8.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-06-30$336.8mus-gaap:AssetsCurrent
Total assetsAt period end2020-06-30$661.3mus-gaap:Assets
Current liabilitiesAt period end2020-06-30$131.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-06-30$321.7mus-gaap:Liabilities
Long-term debtAt period end2020-06-30$159.4mus-gaap:LongTermDebtNoncurrent
Short-term borrowingsAt period end2020-06-30$0us-gaap:ShortTermBorrowings
Shareholders' equityAt period end2020-06-30$339.7mus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Source: SEC EDGAR, the filing index for accession 0001564590-20-038321. Last ingested by Listed: Nov 11, 2026, 00:16 ET. Listed shows no prices and gives no investment advice.